|
Age, n (%)
|
|
<65 years
|
28 (54.9)
|
|
≥65 years
|
23 (45.1)
|
|
Median (range), years
|
64.0 (31–84)
|
|
Sex, n (%)
|
|
Male
|
34 (66.7)
|
|
Female
|
17 (33.3)
|
|
Race, n (%)
|
|
White
|
35 (68.6)
|
|
Asian
|
2 (3.9)
|
|
American Indian or Alaskan
|
1 (2.0)
|
|
Black or African American
|
1 (2.0)
|
|
Other
|
12 (23.5)
|
|
ECOG performance status, n (%)
|
|
0
|
25 (49.0)
|
|
1
|
26 (51.0)
|
|
Site of primary tumor, n (%)
|
|
Cutaneous
|
28 (54.9)
|
|
Ocular
|
16 (31.4)
|
|
Mucosal
|
2 (3.9)
|
|
Othera
|
5 (9.8)
|
|
Time from initial diagnosis to study entry, years
| |
|
Median
|
4.3
|
|
Range
|
0.3–33.5
|
|
Time since first metastatic disease, months
|
|
Median
|
14.8
|
|
Range
|
2.3–168.9
|
|
PD-L1 expression (≥1% of tumor cells), n (%)
|
|
Positive
|
19 (37.3)
|
|
Negative
|
20 (39.2)
|
|
Not evaluable
|
12 (23.5)
|
|
Number of prior lines of therapy for metastatic or locally advanced disease, n (%)
|
|
0
|
1 (2.0)
|
|
1
|
23 (45.1)
|
|
2
|
17 (33.3)
|
|
≥3
|
9 (18.0)
|
|
Missing
|
1 (2.0)
|
|
Median (range)
|
2 (0–4)
|
|
Prior anticancer therapy in >5% of patients, n (%)
|
|
Ipilimumab
|
26 (51.0)
|
|
Dacarbazine
|
11 (21.6)
|
|
Cisplatin
|
8 (15.7)
|
|
Interferon
|
6 (11.8)
|
|
Fotemustine
|
5 (9.8)
|
|
Gemcitabine
|
5 (9.8)
|
|
Treosulfan
|
5 (9.8)
|
|
Vemurafenib
|
5 (9.8)
|
|
Investigational drug
|
4 (7.8)
|
|
Paclitaxel
|
3 (5.9)
|
|
Sorafenib
|
3 (5.9)
|
